Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma
出版年份 2021 全文链接
标题
Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma
作者
关键词
-
出版物
Frontiers in Oncology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-06-04
DOI
10.3389/fonc.2021.658690
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Accelerated Partial Breast Irradiation: Macrophage Polarisation Shift Classification Identifies High-Risk Tumours in Early Hormone Receptor-Positive Breast Cancer
- (2020) Sören Schnellhardt et al. Cancers
- PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
- (2020) Brian Diskin et al. NATURE IMMUNOLOGY
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
- (2020) Manuela Terranova-Barberio et al. Nature Communications
- The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
- (2020) Yanhui Chen et al. Experimental Hematology & Oncology
- Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy
- (2020) Shoujian Ji et al. BIOMEDICINE & PHARMACOTHERAPY
- Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma
- (2019) Pok Fai Wong et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Tumor-associated macrophages: role in cancer development and therapeutic implications
- (2019) Arash Salmaninejad et al. CELLULAR ONCOLOGY
- Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
- (2019) Sonja Althammer et al. Journal for ImmunoTherapy of Cancer
- LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
- (2019) L Paz-Ares et al. ANNALS OF ONCOLOGY
- Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy
- (2019) Yuting Liu et al. CLINICAL CANCER RESEARCH
- OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
- (2019) M. Garassino et al. Journal of Thoracic Oncology
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment
- (2017) Mark A. J. Gorris et al. JOURNAL OF IMMUNOLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice
- (2016) Lingxiang Kong et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells
- (2016) Xin Liu et al. Scientific Reports
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
- (2012) Sergei I. Grivennikov et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started